Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BUM1
UPID:
G6PC3_HUMAN
Alternative names:
Glucose-6-phosphatase beta; Ubiquitous glucose-6-phosphatase catalytic subunit-related protein
Alternative UPACC:
Q9BUM1; Q8WU15
Background:
Glucose-6-phosphatase 3, also known as Glucose-6-phosphatase beta, plays a crucial role in glucose metabolism by hydrolyzing glucose-6-phosphate to glucose in the endoplasmic reticulum. This process is vital for glucose production through glycogenolysis and gluconeogenesis, in collaboration with the glucose-6-phosphate transporter (SLC37A4/G6PT), forming a complex that is ubiquitously expressed across various tissues.
Therapeutic significance:
The protein is implicated in severe congenital Neutropenia 4, autosomal recessive, characterized by a maturation arrest of granulopoiesis, and Dursun syndrome, marked by pulmonary arterial hypertension and hematological abnormalities. Understanding the role of Glucose-6-phosphatase 3 could open doors to potential therapeutic strategies for these conditions.